Metropolis Healthcare Limited share price

NSE: METROPOLIS · ISIN INE112L01020

Key numbers

Market cap: ₹ 12,086 Cr
Current price: ₹ 582.60
52-week high / low: ₹ 609 / 412
Stock P/E: 59.9
Book value: ₹ 73.0
Dividend yield: 0.34%
ROCE: 17.3%
ROE: 13.4%
Debt to equity: 0.15
Sales growth (3 yrs): 12.8%
Profit growth (3 yrs): 10.0%
1-year return: 11.9%

About Metropolis Healthcare Limited

Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India and internationally. The company offers routine and specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; clinical trial research, hospital lab management, and home collection services; radiology services, including X-ray, sonography and ECG; and next-generation sequencing services. It also provides diagnostic services for oncology, chronic and infectious diseases, gastroenterology, neurology, nephrology, and women and child health, as well as various health checkup and laboratory services. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, mobile app, website, and home collection; partnerships with standalone labs, hospital chains, and diagnostic networks; and institutional clients, such as corporates, government bodies, and hospital lab management services. Metropolis Healthcare Limited was founded in 1980 and is headquartered in Mumbai, India.

Quarterly results

Consolidated figures in ₹ crores

	Mar 2025	Jun 2025	Dec 2025	Mar 2026	Jun 2026
Sales	345	386	406	425	450
Operating profit	62	90	95	108	111
Net profit	29	45	41	51	57
EPS (₹)	-	2.17	2.00	2.46	2.73

Concall summary (2026-09-02)

AI summary of the earnings call transcript · tone: Positive · source document

Guidance & outlook

But c urrently where we are at about $ 11 billion, we're expecting over the next eight years this should move to approximately $28.5 billion at about 11% CAGR.
So what we are confident is that the number of projects that we can take up in this coming year will be much higher and next year, when we go to the next year, I think we will see the results of whatever, what all we are doing in this year.

Growth & demand

This is a business in which we need to deliver consistently year-on-year, outpacing the industry growth and you automatically will land up making good returns in the future because the structural flow for the industry is so strong, where less than 6% of Indians have ever been diagnosed.
We have very clearly, distinctly 5 growth engines, for as far as the business growth is concerned, to deliver the sustainable and profitable business growth.

Margins & costs

Our EBITDA has also Metropolis Healthcare Limited August 27, 2026 grown at about 18.6% CAGR for three years and last year was 23% a nd the same thing with PAT, very similar numbers.
We service around 2200-odd pincodes that are there, and the D2C, the digital piece around that, ensures that we have a lower acquisition cost of acquiring the customers as well as almost 2x of the LTV of a regular lifetime value of the regular customer coming through our offline channels.

Capex & expansion

As we saw last year, our North India contribution was less than 10%, about 7 %-8%, and we've managed to move this up by 10% in a year's time because we did some interesting acquisitions last year and they're using that as a base to grow North India very quickly.
On the B2B side, what is also adding up and what is aiding the growth of B2B I mean, the last quarter was 15%-odd is the addition of Core test menu after the acquisition of Core Diagnostics.

Balance sheet & cash

We recently did the bonus issue of 3:1, sort of a split bonus that we did and we usually do a dividend.
We are looking forward to automate our receivables management, automate our supply chain with the vendors.

Peers in Diagnostics & Research

Data for information only, not investment advice. Prices end of day.